Future Role of Checkpoint Inhibitors in Melanoma

Video

For High-Definition, Click

Tolerability and the development of predictive biomarkers that guide treatment selection will determine the future role of checkpoint inhibitors in melanoma, believes Omid Hamid, MD. Past trials have highlighted the toxicity involved in the combination of BRAF and CTLA-4 therapies, particularly ALT/AST increase and bowel perforation. Additionally, side effects were a concern with the combination of nivolumab and ipilimumab. However, the combination of ipilimumab and T-VEC appeared to be well tolerated, Hamid adds.

At this point, research suggesting which patients are more prone to high toxicity is scarce, notes Hamid. Moreover, the time point that side effects occur and an optimal treatment remains elusive. With experience, many of the side effects associated with dual targeted therapy has been addressed, suggesting that time could provide treatment clues for immunotherapy as well. At this point, it seems likely that the answer for both benefit and toxicity lies in biomarker development, Hamid suggests.

The realization of added toxicity with combinations is important to point out, since the temptation to create individualized experimental regimens is high, given excitement around these agents, Louis M. Weiner, MD, states. Clinical trials are still needed that explore combinations, not only to cull out the benefits but also the toxicity. This is even more important as the reimbursement world changes, suggests Robert Dreicer, MD. Outside of a clinical trial, reimbursement for the experimental use of therapies is unlikely.

Many of the studies that are needed to provide clues on combinations and biomarkers are already accruing patients, notes Hamid. Additionally, drugs that have shown promise in the metastatic setting are being explored in the adjuvant space and in combinations.

Roy S. Herbst, MD, PhD, suggests that another question that needs to be asked is why aren't patients responding to therapy? To answer this, more research is needed into biomarkers, believes Weiner. In many situations, PD-L1 status by itself is unlikely to be the only biomarker that is needed, particularly since patients who tested PD-L1 negative in clinical trials still responded to treatment. To answer this question, studies examining MPDL3280A are looking at markers of T cell activation, changes in PD-L1 staining, and gene arrays, notes Hamid.

Related Videos
Sangeeta Goswami, MD, PhD, of The University of Texas MD Anderson Cancer Center
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Andrew Ip, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.
In this third episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential benefits of utilizing immunotherapy approaches earlier on in the disease course.
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Arya Amini, MD
Adrianna Masters, MD, PhD,
Related Content
Professor Lindy Durrant

SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma

April 22nd 2024
Article
FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022
Podcast
FDA

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

April 18th 2024
Article
Sorting Through Sexism, Guilt, and Motherhood in Medicine

Sorting Through Sexism, Guilt, and Motherhood in Medicine

January 27th 2022
Podcast
Elizabeth Plimack, MD, MS, FASCO

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024
Article
Ritu Salani, MD

Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy’s Entrance Into dMMR Endometrial Cancer

April 16th 2024
Article